Cedar Capital’s Bristol-Myers Squibb BMY Stock Holding History

Cedar Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,149	Closed	-$202K	–	156
2019 Q4	$202K	Buy	+3,149	New	+$180K	0.09%	176

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cedar Capital's BMY Position: Q1 2020 in Review

Cedar Capital sold out of Bristol-Myers Squibb (BMY) in Q1 2020, closing a stake of 3,149 shares — an estimated $202K sold.

Cedar Capital first reported a position in BMY in Q4 2019 and held it in 1 quarter. The position peaked at $202K in Q4 2019. 2,148 funds tracked by Wall St. Rank hold BMY as of Q1 2020.

Cedar Capital reported no remaining Bristol-Myers Squibb position as of Q1 2020 after selling out during the quarter.
Cedar Capital sold 3,149 Bristol-Myers Squibb shares in Q1 2020, an estimated $202K.
Cedar Capital first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 1 quarter.
Cedar Capital's Bristol-Myers Squibb position peaked at $202K in Q4 2019.
2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2020.

Based on Cedar Capital's 13F filing for Q1 2020, filed 23 Apr 2020.